All In Biotech

Drug Trial Radar · NCT04612413

A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients

A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients

Last checked: Nov 19, 2026Latest source record: Aug 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 148 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

148

Actual

Start

Nov 30, 2020

Primary completion

Jan 12, 2024

Study completion Dec 16, 2024

Sponsor

Lead sponsor
Enlivex Therapeutics Ltd.Industry
Sponsor type
Industry
First posted
Nov 3, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients

Conditions

  • Sepsis
  • Community-acquired Pneumonia
  • Urinary Tract Infections
  • Cholecystitis, Acute
  • Cholangitis Acute
  • Intraabdominal Infections

Interventions

  • Allocetra-OTSDrug

    Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state and suspended in a solution containing DMSO.

  • PlaceboOther

    Solution containing all excipients except for the Allocetra-OTS cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy: Change from baseline in SOFA scoreTime frame: 28 days
  2. Safety: Number and severity of AEs and SAEsTime frame: 28 days

Locations

31 sites in 5 countries. Site status is shown where the registry gives one.

  • Clinique Saint-Pierre

    Brussels, Belgium

  • Saint-Luc Hospital University

    Brussels, Belgium

  • CHU de Charleroi

    Charleroi, Belgium

  • Ziekenhuis Oost-Limburg

    Genk, Belgium

  • CHU d'Angers

    Angers, France

  • Vendee Departmental Hospital Center

    La Roche-sur-Yon, France

  • University Hospital of Limoges

    Limoges, France

  • CHU de Montpellier

    Montpellier, France

  • CHU de Nantes

    Nantes, France

  • Bretonneau Hospital

    Paris, France

  • Centre Hospitalier Victor Dupouy

    Paris, France

  • Reims University Hospital Robert Debre

    Reims, France

  • CHU de Rennes

    Rennes, France

  • Strasbourg University Hospital

    Strasbourg, France

  • Soroka Medical Center

    Beersheba, Israel

  • Hillel Yaffe Medical Center

    Hadera, Israel

  • Bnai Zion Medical Center

    Haifa, Israel

  • Hadassah Ein Kerem Medical Center

    Jerusalem, Israel

  • Beilinson Medical Center

    Petah Tikva, Israel

  • Ziv Medical Center

    Safed, Israel

  • Poriya Medical Center

    Tiberias, Israel

  • Canisius Wilhelmina Hospital

    Nijmegen, Netherlands

  • Radboud UMC

    Nijmegen, Netherlands

  • Clinic Barcelona University Hospital

    Barcelona, Spain

  • University Hospital Sagrat Cor

    Barcelona, Spain

  • Vall d'Hebron

    Barcelona, Spain

  • Getafe University Hospital

    Getafe, Spain

  • Dr. Josep Trueta University Hospital

    Girona, Spain

  • University Hospital Arnau de Vilanova of Lleida

    Lleida, Spain

  • General University Hospital Gregorio Maranon

    Madrid, Spain

  • University Hospital Joan XXIII of Tarragona

    Tarragona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.